Stabilization of Calcium Oxalate Precursors during the Pre- and Post-Nucleation Stages with Poly(acrylic acid).
amorphous calcium oxalate (ACO)
calcium oxalate
poly(acrylic acid)
pre-nucleation clusters
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
18 Jan 2021
18 Jan 2021
Historique:
received:
15
12
2020
revised:
03
01
2021
accepted:
04
01
2021
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
23
1
2021
Statut:
epublish
Résumé
In this work, calcium oxalate (CaOx) precursors were stabilized by poly(acrylic acid) (PAA) as an additive under in vitro crystallization assays involving the formation of pre-nucleation clusters of CaOx via a non-classical crystallization (NCC) pathway. The in vitro crystallization of CaOx was carried out in the presence of 10, 50 and 100 mg/L PAA by using automatic calcium potentiometric titration experiments at a constant pH of 6.7 at 20 °C. The results confirmed the successful stabilization of amorphous calcium oxalate II and III (ACOII and ACO III) nanoparticles formed after PNC in the presence of PAA and suggest the participation and stabilization of polymer-induced liquid-precursor (PILP) in the presence of PAA. We demonstrated that PAA stabilizes CaOx precursors with size in the range of 20-400 nm. PAA additive plays a key role in the in vitro crystallization of CaOx stabilizing multi-ion complexes in the pre-nucleation stage, thereby delaying the nucleation of ACO nanoparticles. Indeed, PAA additive favors the formation of more hydrated and soluble phase of ACO nanoparticles that are bound by electrostatic interactions to carboxylic acid groups of PAA during the post-nucleation stage. These findings may help to a better understanding of the pathological mineralization resulting in urolithiasis in mammals.
Identifiants
pubmed: 33477452
pii: nano11010235
doi: 10.3390/nano11010235
pmc: PMC7829898
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Faraday Discuss. 2007;136:265-77; discussion 309-28
pubmed: 17955814
Urology. 2008 Feb;71(2):209-13
pubmed: 18308085
Urolithiasis. 2016 Aug;44(4):311-7
pubmed: 26920852
Urol Res. 2005 Aug;33(4):267-72
pubmed: 15937709
Curr Opin Nephrol Hypertens. 2017 Jul;26(4):256-265
pubmed: 28410252
Urolithiasis. 2017 Feb;45(1):57-74
pubmed: 27913854
Adv Sci (Weinh). 2019 Aug 20;6(19):1900683
pubmed: 31592093
J Am Chem Soc. 2008 Sep 17;130(37):12342-7
pubmed: 18717561
World J Urol. 2017 Sep;35(9):1301-1320
pubmed: 28213860
Pediatr Nephrol. 2010 May;25(5):831-41
pubmed: 19198886
Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2141-6
pubmed: 25278549
J Struct Biol. 2016 Nov;196(2):260-287
pubmed: 27620641
Chem Rev. 2008 Nov;108(11):4551-627
pubmed: 19006398
Nat Commun. 2017 Oct 3;8(1):768
pubmed: 28974672
Rev Urol. 2009 Summer;11(3):134-44
pubmed: 19918339
Keio J Med. 1997 Mar;46(1):1-9
pubmed: 9095576
J Urol. 2008 Apr;179(4):1615-9
pubmed: 18295252
Urol Clin North Am. 2007 Aug;34(3):287-93
pubmed: 17678980
Science. 2008 Dec 19;322(5909):1819-22
pubmed: 19095936
Biochemistry. 1996 Nov 26;35(47):14703-9
pubmed: 8942630
Talanta. 1996 Sep;43(9):1497-509
pubmed: 18966629
Nat Commun. 2018 Jul 3;9(1):2582
pubmed: 29968713
J Urol. 1956 Sep;76(3):213-27
pubmed: 13368269